Development of new generation influenza vaccines

Development of new generation influenza vaccines

Highlights ► Vaccines are time-proven and promising response to human infectious diseases. ► Productivity gap: approximately 80% attrition rate in vaccine development. ► Recipe for success: planning, simplify, relevance, and learning from failure.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Vaccine 2012-12, Vol.30 (51), p.7344-7347
Hauptverfasser: Pronker, E.S, Claassen, E, Osterhaus, A.D.M.E
Format: Artikel
Sprache:eng
Schlagworte:
Allergy and Immunology
Attrition rate
Clinical trials
Collaboration
ESWI conference proceedings
Infectious diseases
Market entry
Market positioning
Public health
Regulatory approval
Startups
Success
Success rate
Vaccine development
Vaccine risk profile
Vaccines
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Highlights ► Vaccines are time-proven and promising response to human infectious diseases. ► Productivity gap: approximately 80% attrition rate in vaccine development. ► Recipe for success: planning, simplify, relevance, and learning from failure.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2012.09.071